Enzon 1Q

1Q Revenues: $48.6 million (flat)

1Q Earnings: $6.2 million (earnings were $1.5 million in 1Q08)

Comments: Oncaspar sales were up 15% to $14.1 million. DepoCyt sales were $2.5 million (+25%). Abelcet sales were down 16% to $5.9 million. Adagen sales were $7.2 million (+18%). Royalty revenue was $13.6 million (-7%). Contract manufacturing revenue was $5.3 million (-20%).